Another pneumonic plague case in Russia by...?

According to the latest prediction market data for the query “Another pneumonic plague case in Russia by...?”, traders have formed a strong consensus.

Currently, October 31, 2026 is dominating the market with an overwhelming 4.5% chance of winning. October 15, 2026 follows in second place at 1.9%. The betting volume for this specific market has already reached $88.1K, reflecting intense industry interest.

To better assess where each potential outcome stands, the market can be segmented into three distinct trading tiers based on implied probability and contract pricing:

🥇 Tier 1: The Dominant Leader

• October 31, 2026 (4.5%): Currently commanding the highest probability, October 31, 2026 is heavily favored by the order book. Traders looking to back this outcome face a “Buy Yes” contract price of 5¢, signaling a high degree of market conviction. This contract alone has generated $48.3K in volume.

🥈 Tier 2: The Primary Challengers

• October 15, 2026 (1.9%): Positioned as the most viable alternative, October 15, 2026 maintains a 1.9% chance of resolving true. Its “Buy Yes” shares currently trade at 2¢.

This market will resolve to "Yes" if a confirmed case of pneumonic plague in a human is reported in the Russian Federation at any point between market creation and the specified date, 11:59 PM Moscow time, . Otherwise, this market will resolve to "No".

A "confirmed case" is a case explicitly identified by a qualifying source as laboratory-confirmed Yersinia pestis infection with pneumonic (pulmonary) involvement, or explicitly announced as a confirmed pneumonic plague case. Publication of the underlying laboratory results is not required. A bubonic or septicemic case that progresses to pneumonic plague qualifies. A case reported only as "plague" with no form specified, and a case described only as suspected or probable, do not qualify.

The case must be distinct from the Irkutsk Anti-Plague Research Institute employee who reportedly passed away on October 1, 2026; subsequent confirmation, reclassification, or post-mortem testing of that patient will not qualify. Resolution turns on the date a qualifying source publishes the confirmation, not the date of exposure, symptom onset, or laboratory result. A report published after the deadline does not count even if the infection occurred earlier.

The primary resolution sources for this market will be official information from Russian federal or regional public health authorities and the WHO; however a consensus of credible sources will also suffice.

While human consensus and speculative volume shape the broader prediction market, our quantitative algorithms offer a data-driven counter-perspective. By analyzing fundamental signals, underlying trends and historical distributions, our AI Valuation model calculates an independent “Fair Value” probability for each outcome.

Comparing this Fair Value against the current Trade Value uncovers major disparities — known as the Expected Value (EV) Gap. Contracts with a positive EV Gap represent statistically underpriced outcomes, whereas a negative EV Gap flags a potential market overreaction.

Top AI Alpha & Mispriced Arbitrage Opportunities

Based on the latest data model run, several key contracts stand out with significant deviations:

• The Best Value Play (Highest EV) Our model identifies October 31, 2026 as the premium value opportunity on the board. While the market only assigns it a 4.5% trading probability, our AI’s Fair Value assessment sits at 14.2% — yielding an impressive +9.7% EV Gap.
• Under-the-Radar Dark Horses Other notable discrepancies include October 15, 2026 (EV Gap: +9.1%). These long-tail opportunities are heavily discounted by the live order books despite stronger statistical backing from our predictive model.